[A multicenter clinical trial of piperacillin/tazobactam in burn infection].
OBJECTIVE
To evaluate the efficacy of piperacillin/tazobactam in the management of burn infection.


METHODS
Sixty-three burn patients were enrolled in the study with burn sepsis or burn area more than 50%TBSA or full skin loss more than 30% TBSA. The administration regime of the antibiotics was 4.5 g intravenously administered every 8 hours in the treatment of burn sepsis or in the prophylactic management. The effectiveness was identified when the septic symptoms disappeared or focal infection did not develop into sepsis.


RESULTS
The overall clinical efficacy was 90.4%, and success in sepsis (control) was 75%. Furthermore, 95.7% of the focal infection was prevented from developing into systemic infection. The bacterial clearance rates were 71.4% and 51.4% in treatment and prophylaxis groups, respectively.


CONCLUSIONS
Piperacillin/taxobactam was effective in the treatment and/or prophylaxis of burn sepsis caused by bacteria susceptible to it, so it could be applied empirically.
Xu
Weishi
W
Burn Institute, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, P. R. China.
Deng
Shilin
S
Han
Chunmao
C
Li
Xiaojian
X
Liao
Zhenjiang
Z
Wang
Wenkui
W
D000328:Adult; D002056:Burns / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010878:Piperacillin / Q000627:therapeutic use*; D018805:Sepsis / Q000209:etiology / Q000517:prevention & control; D000078142:Tazobactam; D016896:Treatment Outcome
D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin